Examination of NP12 and BDNF nanoparticle combo-treatment as a potential therapeutic for Alzheimer Disease
Dominic Arruda ’22
Faculty Mentor: Dr. Victoria Templer, Psychology
Alzheimer’s Disease is a neurodegenerative disorder that afflicts approximately 44 million individuals worldwide. Although previous research has shown that BDNF therapeutics may serve as an efficient treatment for reducing the progression of cognitive and behavioral deficits, the results suggest that such methods had little effect in decreasing the development of neurofibrillary tangles. To address previous safety and efficacy limitations in the current study, Tg2676 mice were treated with nanoparticles containing BDNF, NP12 (a GSK 3B inhibitor), BDNF and NP12 (combo treatment), or no treatment. Nanoparticles were injected prior to the onset of spatial memory deficits to assess whether treatment may lead to a delay in symptom onset and severity. BDNF, AB, and hyperphosphorylated tau were assessed using ELISA; spatial memory was assessed around the expected time of spatial memory deficit via a Morris water maze.
4-29-2021 12:00 AM